Fig 5.
Superior clinical outcomes among patients receiving total therapy 2 (TT2) with gene expression profiling (GEP)-defined standard-risk versus high-risk myeloma. (A) Overall survival was highly superior in the low- versus high-risk group. (B) Event-free survival was highly superior in the low- versus high-risk group. (C) Duration of complete remission (CR) was highly superior in the low- versus high-risk group.
